Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by J. Pinilla-Ibarz
Fixed-Duration Venetoclax Plus Obinutuzumab Improves PFS and Minimal Residual Disease Negativity in Patients With Previously Untreated CLL and Comorbidities
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Obinutuzumab Plus Bendamustine in Previously Untreated Patients With CLL: A Subgroup Analysis of the GREEN Study
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Ongoing Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Sakk 35/15: A Phase I Trial of Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Venetoclax–Obinutuzumab Elicits High Response Rates in CLL
Cancer Discovery
Oncology
Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia
Blood
Biochemistry
Immunology
Cell Biology
Hematology
High Efficacy of Venetoclax Plus Obinutuzumab in Patients With Complex Karyotype (Ckt) and Chronic Lymphocytic Leukemia (Cll): A Prospective Analysis From the Cll14 Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Profile of Obinutuzumab for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
OncoTargets and Therapy
Oncology
Pharmacology
Bendamustine (B), Followed by Obinutuzumab (G) and Venetoclax (A) in Patients With Chronic Lymphocytic Leukemia (Cll): Cll2-Bag Trial of the German CLL Study Group (Gcllsg)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Venetoclax: Another Oral Therapy Option for Patients With CLL
Pharmacy Today
